HGH and Heart Health: What Cardiac Research Actually Shows
Updated: 3 days ago
By HGHThailand Team
HGH and heart health are connected in two directions. Persistently high levels, as in acromegaly, are linked to arrhythmias, structural heart changes and higher cardiovascular mortality. In adults with a confirmed GH deficiency, replacement therapy under specialist care has been associated with better body composition and some cardiac measures. The two situations call for different medical responses, and neither one is a reason to self-treat.
Key points
Excess GH (acromegaly) is a recognised cause of cardiovascular complications and reduced life expectancy.
Adult GH deficiency is associated with increased fat mass, impaired cardiac function and higher overall morbidity. GH replacement is a medical treatment for that diagnosis, not a wellness product.
Controlled trials of GH in healthy, fit young adults found no improvement in strength or exercise capacity, but more soft-tissue swelling and fatigue.
Somatropin is a prescription medicine with specific approved indications. Anti-aging and athletic uses are not among them.
Chest pain, breathlessness, palpitations or fainting need prompt medical assessment, not a hormone explanation.
What growth hormone actually does
GH is a peptide hormone released by the pituitary gland in pulses, mainly during deep sleep. It acts partly directly and partly through insulin-like growth factor 1 (IGF-1), produced largely by the liver; together they influence growth, body composition and how the body handles fat, protein and glucose. Levels peak in childhood and puberty, then decline with age, a normal pattern, not a diagnosis on its own (see What is HGH?). The heart responds to these signals; this link between growth hormone and cardiac function is why too little or too much GH can surface as cardiac problems.
How Does High Growth Hormone Affect the Heart? (Acromegaly)
Acromegaly is a chronic condition of GH excess, usually caused by a GH-secreting pituitary tumour (more than 95% of cases; Iglesias, 2025). Acromegaly heart complications are among the main reasons the condition increases illness and shortens life. A 2024 review in *Endocrine Practice* defines acromegalic cardiomyopathy as concentric biventricular hypertrophy with diastolic dysfunction (thickening and stiffening of the heart muscle) once other causes such as hypertension and diabetes are excluded. It names arrhythmias and sudden cardiac death as the most common contributors to increased cardiovascular mortality, and reports that the *duration* of GH excess predicts heart failure and valvular disease more strongly than the degree of hormone elevation (Sherin and colleagues, 2024).
A 2025 review in the *Journal of Clinical Medicine* adds hypertension, dyslipidaemia, coronary artery disease and atherosclerosis to the picture, and notes that bringing GH and IGF-1 back to normal can improve cardiovascular prognosis (Iglesias, 2025). Treatment (surgery, medication or radiotherapy, chosen by a specialist) targets that hormone excess and requires medical management.
Can Growth Hormone Deficiency Cause Heart Problems?
At the other end, adult growth hormone deficiency and cardiovascular risk are linked through increased body-fat mass and abdominal obesity, unfavourable blood-lipid levels, reduced exercise capacity and impaired cardiac function, plus higher overall morbidity (Milioto and colleagues, 2026). In adults with hypopituitarism (reduced pituitary function), GH replacement under supervision has been associated with improved outcomes and a reassuring safety profile, though monitoring is still required.
Two cautions: this evidence concerns people with a *diagnosed* deficiency, not healthy adults; and "associated with improved outcomes" is not a promise of benefit for any individual.
Does Growth Hormone Improve Heart Function or Athletic Performance?
The belief that GH boosts athletic performance is widely repeated but poorly supported. A systematic review of randomised controlled trials in *Annals of Internal Medicine* pooled 27 study samples of physically fit young adults (mean age 27). Lean body mass rose by about 2.1 kg with GH, but strength and exercise capacity did not improve, and participants reported more soft-tissue oedema and fatigue than controls. The authors concluded that claims GH enhances physical performance are not supported by the literature (Liu and colleagues, 2008).
What high-dose GH use has in common with acromegaly
Acromegaly is defined by sustained GH excess. For that reason, clinicians watch for the same cardiovascular problems when GH is used at high doses outside a medical setting. When considering HGH side effects on the heart, researchers point to the structural changes seen in chronic excess. The research does not establish that any particular pattern of use causes a specific heart condition, and most trials here are small and short. What the evidence does show is that dose, duration and medical supervision all affect outcomes, which is why unsupervised high-dose use carries risks that monitored treatment is designed to catch early.
"Studied in research" is not the same as "approved for use"
Somatropin (recombinant human GH) is a prescription medicine, one of several recombinant human growth hormone formulations. Its US labelling lists specific approved indications for clinical growth hormone therapy, for example, replacement therapy in adults with GH deficiency, and certain childhood growth disorders. Anti-aging, "wellness" and athletic uses are not approved indications: an effect seen in research is not the same as an approved, monitored use, and using a prescription product outside its indication carries unmonitored risks. Somatropin belongs to the wider growth hormone category.
Heart symptoms: get them checked
Shortness of breath, chest pain or pressure, palpitations, fainting, or new swelling and rapid fluid weight gain are reasons to see a doctor promptly, not to start, stop or adjust a hormone. Cardiac symptoms have many possible causes, and self-diagnosis can delay real treatment.
FAQ
Does HGH affect heart health?
Yes, in both directions. Long-term excess GH (acromegaly) is linked to arrhythmias, heart-muscle changes and higher cardiovascular mortality. In adults with a diagnosed GH deficiency, replacement treatment has been associated with improved cardiac and metabolic measures.
Can HGH cause heart problems?
Sustained GH excess (as in acromegaly) is a recognised cause of cardiomyopathy, hypertension and valvular disease. Whether high-dose non-medical use causes the same changes is not established by the research.
Can HGH therapy improve heart function?
In adults with confirmed GH deficiency and hypopituitarism, supervised replacement has been associated with improved cardiac and metabolic outcomes in reviews and cohort studies. This applies to diagnosed deficiency, not to healthy adults.
Is HGH approved for anti-aging or athletic use?
No. Somatropin is approved for specific medical indications such as GH-deficiency replacement and certain childhood growth disorders. Anti-aging and athletic-enhancement uses are outside those approved indications.
Disclaimer: This article is for general information only and not medical advice; it does not diagnose, treat, cure or prevent any condition. Growth hormone medicines are prescription products; only a qualified healthcare professional can assess your situation. If you have cardiac symptoms, seek medical attention.
Sources
Liu H, Bravata DM, Olkin I, et al. "Systematic review: the effects of growth hormone on athletic performance." *Annals of Internal Medicine*, 2008;148(10):747–758. PubMed: https://pubmed.ncbi.nlm.nih.gov/18347346/
Sherin RPV, Vietor NO, Usman A, Hoang TD, Shakir MKM. "Cardiovascular Disorders Associated With Acromegaly: an Update." *Endocrine Practice*, 2024;30(12):1212–1219. PubMed: https://pubmed.ncbi.nlm.nih.gov/39332498/
Iglesias P. "Acromegaly and Cardiovascular Disease: Associated Cardiovascular Risk Factors, Cardiovascular Prognosis, and Therapeutic Impact." *Journal of Clinical Medicine*, 2025;14(6):1906. PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC11943432/
Milioto A, Esposito D, Johannsson G, Ragnarsson O. "Cardiovascular and metabolic outcomes of GH replacement therapy in adults with GH deficiency: gender gaps." *Pituitary*, 2026;29(2):43. PubMed: https://pubmed.ncbi.nlm.nih.gov/41718895/ · PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC12923456/
U.S. Food and Drug Administration. "ZOMACTON (somatropin) for injection: Prescribing Information (INDICATIONS AND USAGE)." 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/019774s063lbl.pdf